| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Secoisolariciresinol diglucoside (SDG) targets multiple pathways. It functions as an antagonist of the platelet activating factor receptor and inhibits myeloperoxidase (MPO) activity by suppressing both the peroxidase and chlorination cycles in inflammatory cells. It also acts as a potent antioxidant, scavenging free radicals and reducing reactive oxygen species (ROS) levels. By inhibiting MPO and reducing ROS, SDG modulates inflammatory responses and protects against oxidative damage, contributing to its diverse biological activities.
|
|---|---|
| ln Vitro |
In vitro, Secoisolariciresinol diglucoside (SDG) exhibits potent antioxidant and free radical scavenging activities. It inhibits myeloperoxidase (MPO) activity in inflammatory cells. SDG (50 µM) significantly inhibits radiation-induced DNA damage, as evidenced by reduced comet tail length in various lung cell types, without eliciting adverse effects on colony-forming ability. It also reduces lipid peroxidation and shows antiproliferative activity against cancer cells. Additionally, SDG has been shown to inhibit ROS levels, thereby preventing peroxidation damage.
|
| ln Vivo |
In vivo, Secoisolariciresinol diglucoside (SDG) has demonstrated significant biological activities. In a rabbit model of hypercholesterolemic atherosclerosis, oral administration of SDG (15 mg/kg) reduced total cholesterol and LDL-C by 33% and 35%, respectively, while increasing HDL-C by over 140%. This resulted in a 73% reduction in atherosclerosis. The effect was attributed to a decrease in serum cholesterol, LDL-C, and lipid peroxidation products, along with an increase in antioxidant reserve. SDG (25 mg/kg) also exerts antihyperglycemic effects by preventing liver peroxidation damage through inhibition of ROS.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Secoisolariciresinol diglucoside (SDG) typically involve measuring its antioxidant capacity through cell-free systems like DPPH or ABTS radical scavenging assays to determine its free radical scavenging activity. Its inhibition of myeloperoxidase (MPO) activity can be assessed by incubating the compound with the enzyme and a substrate, then measuring the reduction in peroxidase or chlorination activity spectrophotometrically. The compound's ability to inhibit lipid peroxidation is commonly evaluated using the thiobarbituric acid reactive substances (TBARS) assay with lipid-rich preparations such as rat liver microsomes.
|
| Cell Assay |
In vitro cellular assays for Secoisolariciresinol diglucoside (SDG) are performed using various cell lines to assess its cytoprotective and antiproliferative effects. For DNA radioprotection studies, lung cells are pre-treated with SDG and then exposed to radiation, with DNA damage quantified by the comet assay. The compound's anti-inflammatory activity is evaluated in immune cells by measuring its ability to inhibit MPO activity and reduce ROS production. Antiproliferative effects are assessed in cancer cell lines using standard viability assays such as MTT or SRB, where cells are treated with SDG for 48-72 hours to determine IC50 values.
|
| Animal Protocol |
In vivo animal experiments for Secoisolariciresinol diglucoside (SDG) have been conducted in rabbit models of hypercholesterolemic atherosclerosis. In these studies, rabbits were fed a high-cholesterol diet and orally administered SDG (15 mg/kg). After 8 weeks, serum lipid profiles were measured, and aortic atherosclerosis was assessed. In another study, SDG (25 mg/kg) was administered orally to mice to evaluate its antihyperglycemic effects, with blood glucose levels and markers of liver peroxidation measured. These models help elucidate SDG's cardioprotective and antidiabetic properties.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Secoisolariciresinol diglucoside (SDG) indicate that it is orally bioavailable, as demonstrated by its efficacy in animal models following oral administration. As a lignan glycoside, it is likely metabolized by gut microbiota to its aglycone, secoisolariciresinol, and further to enterolignans such as enterodiol and enterolactone, which are absorbed and can exert systemic effects. However, detailed PK parameters such as half-life, Cmax, and bioavailability are not extensively detailed in publicly available sources for the parent compound.
|
| Toxicity/Toxicokinetics |
Toxicological data for Secoisolariciresinol diglucoside (SDG) are limited in publicly available sources. As a natural lignan found in flaxseed, which has a long history of dietary consumption, it is generally considered to have a low toxicity profile. In in vitro studies, SDG at concentrations of 10-50 µM did not elicit any adverse effects on the colony-forming ability of lung cells. No significant acute or chronic toxicity has been reported in the available literature, though comprehensive toxicological assessments are not widely published.
|
| References |
|
| Additional Infomation |
It has been reported that flax (Linum usitatissimum) contains Secoisolariciresinol diglucoside, and relevant data has been published. See also: Flaxseed (partial); Sesame (partial); Sunflower seed (partial)... See more...
Secoisolariciresinol diglucoside is a plant lignan found predominantly in flaxseed. It is also known as (R,R)-SDG and LGM2605. Its mechanism of action involves antioxidant activity, MPO inhibition, and platelet activating factor receptor antagonism. It is being studied for its potential in preventing and treating various diseases, including cardiovascular disease, diabetes, and cancer. It is not an approved drug but is widely used as a research compound and nutraceutical. |
| Molecular Formula |
C32H46O16
|
|---|---|
| Molecular Weight |
686.6981
|
| Exact Mass |
686.278
|
| CAS # |
158932-33-3
|
| Related CAS # |
Secoisolariciresinol diglucoside;257930-74-8;Secoisolariciresinol;29388-59-8;Secoisolariciresinol Monoglucoside;63320-67-2
|
| PubChem CID |
9917980
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
989.2±65.0 °C at 760 mmHg
|
| Flash Point |
552.0±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.655
|
| LogP |
-2.79
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
48
|
| Complexity |
861
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
COC1=C(C=CC(=C1)C[C@@H](CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)[C@@H](CC3=CC(=C(C=C3)O)OC)CO[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
|
| InChi Key |
SBVBJPHMDABKJV-PGCJWIIOSA-N
|
| InChi Code |
InChI=1S/C32H46O16/c1-43-21-9-15(3-5-19(21)35)7-17(13-45-31-29(41)27(39)25(37)23(11-33)47-31)18(8-16-4-6-20(36)22(10-16)44-2)14-46-32-30(42)28(40)26(38)24(12-34)48-32/h3-6,9-10,17-18,23-42H,7-8,11-14H2,1-2H3/t17-,18-,23+,24+,25+,26+,27-,28-,29+,30+,31+,32+/m0/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[(2R,3R)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~182.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4562 mL | 7.2812 mL | 14.5624 mL | |
| 5 mM | 0.2912 mL | 1.4562 mL | 2.9125 mL | |
| 10 mM | 0.1456 mL | 0.7281 mL | 1.4562 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
